HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

被引:252
|
作者
Weigelt, Britta [1 ]
Lo, Alvin T. [1 ]
Park, Catherine C. [2 ]
Gray, Joe W. [1 ]
Bissell, Mina J. [1 ]
机构
[1] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Radiat Oncol, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
Breast cancer cell lines; Drug response; Targeted therapy; 3D cell culture; HER2; signaling; MAMMARY EPITHELIAL-CELLS; 3-DIMENSIONAL CULTURE; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; TISSUE ARCHITECTURE; TUMOR-INDUCTION; IN-VIVO; TRASTUZUMAB; GROWTH; RESISTANCE;
D O I
10.1007/s10549-009-0502-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Development of effective and durable breast cancer treatment strategies requires a mechanistic understanding of the influence of the microenvironment on response. Previous work has shown that cellular signaling pathways and cell morphology are dramatically influenced by three-dimensional (3D) cultures as opposed to traditional two-dimensional (2D) monolayers. Here, we compared 2D and 3D culture models to determine the impact of 3D architecture and extracellular matrix (ECM) on HER2 signaling and on the response of HER2-amplified breast cancer cell lines to the HER2-targeting agents Trastuzumab, Pertuzumab and Lapatinib. We show that the response of the HER2-amplified AU565, SKBR3 and HCC1569 cells to these anti-HER2 agents was highly dependent on whether the cells were cultured in 2D monolayer or 3D laminin-rich ECM gels. Inhibition of beta 1 integrin, a major cell-ECM receptor subunit, significantly increased the sensitivity of the HER2-amplified breast cancer cell lines to the humanized monoclonal antibodies Trastuzumab and Pertuzumab when grown in a 3D environment. Finally, in the absence of inhibitors, 3D cultures had substantial impact on HER2 downstream signaling and induced a switch between PI3K-AKT- and RAS-MAPK-pathway activation in all cell lines studied, including cells lacking HER2 amplification and overexpression. Our data provide direct evidence that breast cancer cells are able to rapidly adapt to different environments and signaling cues by activating alternative pathways that regulate proliferation and cell survival, events that may play a significant role in the acquisition of resistance to targeted therapies.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
  • [1] HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
    Britta Weigelt
    Alvin T. Lo
    Catherine C. Park
    Joe W. Gray
    Mina J. Bissell
    Breast Cancer Research and Treatment, 2010, 122 : 35 - 43
  • [2] Targeting HER2/3 in Breast Cancer
    Hepner A.
    Modi S.
    Jhaveri K.
    Current Breast Cancer Reports, 2017, 9 (2) : 61 - 69
  • [3] Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification
    Tanizaki, Junko
    Okamoto, Isamu
    Takezawa, Ken
    Tsukioka, Sayaka
    Uchida, Junji
    Kiniwa, Mamoru
    Fukuoka, Masahiro
    Nakagawa, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) : 1198 - 1207
  • [4] EVOLUTION OF HER2-TARGETING IN METASTATIC BREAST CANCER
    Bartsch, Rupert
    Balic, Marija
    BREAST CARE, 2022, 17 (06) : 521 - 522
  • [5] Targeting HER2 Positive Breast Cancer with Chemopreventive Agents
    Wahler J.
    Suh N.
    Current Pharmacology Reports, 2015, 1 (5) : 324 - 335
  • [6] HER2 Signaling in Breast Cancer
    Shin, Incheol
    TRANSLATIONAL RESEARCH IN BREAST CANCER, 2021, 1187 : 53 - 79
  • [7] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [8] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [9] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [10] Targeting HER2 heterogeneity in breast cancer
    Hamilton, Erika
    Shastry, Mythili
    Shiller, S. Michelle
    Ren, Rongqin
    CANCER TREATMENT REVIEWS, 2021, 100